Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Common Equity (2016 - 2026)

Cytosorbents filings provide 16 years of Common Equity readings, the most recent being $5.9 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 46.85% to $5.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.9 million, a 46.85% decrease, with the full-year FY2025 number at $5.9 million, down 46.85% from a year prior.
  • Common Equity hit $5.9 million in Q4 2025 for Cytosorbents, down from $9.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $77.3 million in Q1 2021 to a low of $5.9 million in Q4 2025.
  • Median Common Equity over the past 5 years was $24.0 million (2023), compared with a mean of $33.1 million.
  • Biggest five-year swings in Common Equity: surged 262.49% in 2021 and later tumbled 52.7% in 2024.
  • Cytosorbents' Common Equity stood at $62.6 million in 2021, then plummeted by 43.47% to $35.4 million in 2022, then crashed by 33.63% to $23.5 million in 2023, then crashed by 52.7% to $11.1 million in 2024, then tumbled by 46.85% to $5.9 million in 2025.
  • The last three reported values for Common Equity were $5.9 million (Q4 2025), $9.0 million (Q3 2025), and $11.6 million (Q2 2025) per Business Quant data.